文献速递角膜与眼表疾病

紫外光A与核黄素交联治疗进展性圆锥角膜:从实验室到临床实践——25年发展历程

Crosslinking with UV-A and riboflavin in progressive keratoconus: From laboratory to clinical practice - Developments over 25 years.
PubMed 文献 · Prog Retin Eye Res · 2024-06-01

本文综述了角膜胶原交联(CXL)技术25年来的发展,该技术利用核黄素联合紫外光A照射诱导活性氧产生,形成额外共价键以增强角膜生物力学稳定性,是目前唯一能部分针对扩张性疾病发病机制、延缓或阻止角膜失代偿进程的方法,并可加速方案缩短治疗时间,联合个性化地形图引导准分子激光消融可进一步扩大适应证。

要点

  • CXL通过核黄素与紫外光A相互作用产生ROS,形成胶原分子间共价键,增强角膜生物力学强度。
  • CXL是目前唯一能部分针对扩张性疾病发病机制、延缓或阻止角膜失代偿进程的方法。
  • 基于Bunsen-Roscoe光化学定律的加速CXL可缩短治疗时间,同时维持疗效与安全性。

核心结论

  • CXL是目前唯一能部分针对扩张性疾病发病机制、延缓或阻止角膜失代偿进程的方法,否则这些病变将需要角膜移植。
  • CXL过程显著增加胶原基质对消化酶的抵抗力,支持其用于治疗角膜溃疡。
  • 加速CXL可缩短治疗时间,改善临床工作流程和患者依从性,同时维持疗效与安全性。
  • CXL与个性化地形图引导准分子激光消融联合,可使生物力学稳定的角膜规则化并提高视力,无需组织移植,从而长期改善生活质量。

研究设计与样本

  • 本文为综述,总结CXL从实验室到临床实践25年的发展,未报告系统检索范围。

主要发现

  • 核黄素联合紫外光A照射诱导活性氧产生,形成胶原分子间额外共价键,增强角膜生物力学强度。
  • CXL可延缓或阻止扩张性病变的进展,这些病变包括原发性(圆锥角膜或透明边缘性角膜变性)或继发性(屈光激光术后医源性角膜扩张)角膜扩张。
  • 基于Bunsen-Roscoe光化学定律的加速CXL可缩短治疗时间,同时维持疗效与安全性。
  • CXL过程显著增加胶原基质对消化酶的抵抗力,支持其用于治疗角膜溃疡。
  • CXL与个性化地形图引导准分子激光消融联合,可使生物力学稳定的角膜规则化并提高视力,无需组织移植。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Changes in the biomechanical and biochemical properties of the human cornea play an important role in the pathogenesis of ectatic diseases. A number of conditions in primarily acquired (keratoconus or pellucid marginal degeneration) or secondarily induced (iatrogenic keratectasia after refractive laser surgeries) ectatic disorders lead to decreased biomechanical stability. Corneal collagen cross-linking (CXL) represents a technique to slow or even halt the progression of ectatic pathologies. In this procedure, riboflavin is applied in combination with ultraviolet A radiation. This interaction induces the production of reactive oxygen species, which leads to the formation of additional covalent bonds between collagen molecules and subsequent biomechanical corneal strengthening. This procedure is so far the only method that partially interferes etiopathogenetically in the treatment of ectatic diseases that slows or stops the process of corneal destabilization, otherwise leading to the need for corneal transplantation. Besides, CXL process increases markedly resistance of collagenous matrix against digesting enzymes supporting its use in the treatment of corneal ulcers. Since the discovery of this therapeutic procedure and the first laboratory experiments, which confirmed the validity of this method, and the first clinical studies that proved the effectiveness and safety of the technique, it has been spread and adopted worldwide, even with further modifications. Making use of the Bunsen-Roscoe photochemical law it was possible to shorten the duration of this procedure in accelerated CXL and thus improve the clinical workflow and patient compliance while maintaining the efficacy and safety of the procedure. The indication spectrum of CXL can be further expanded by combining it with other vision-enhancing procedures such as individualized topographically-guided excimer ablation. Complementing both techniques will allow a patient with a biomechanically stable cornea to regularize it and improve visual acuity without the need for tissue transplantation, leading to a long-term improvement in quality of life.

来源:Prog Retin Eye Res,查看原文。版权归原作者所有。

引用

  1. Raiskup F, Herber R, Lenk J, et al. Crosslinking with UV-A and riboflavin in progressive keratoconus: From laboratory to clinical practice - Developments over 25 years. Prog Retin Eye Res. 2024. PMID: 38830532. doi:10.1016/j.preteyeres.2024.101276

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。